Business Context and Reporting Period
This Form 6-K filing by Icecure Medical Ltd. covers the month of September 2024, with a report date of September 16, 2024. The filing serves to distribute a press release regarding a clinical study published in the British Journal of Radiology concerning the Company's ProSense® cryoablation system.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical study results and does not contain financial statements or operational financial data.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The primary update is the publication of a study demonstrating a 97.7% technical success rate for ProSense® in treating tumors of the lung, bone, and soft tissues, alongside a confirmation of the procedure's safety profile.
Guidance, Outlook, and Risks
The filing incorporates by reference the "Forward Looking Statements" section from the accompanying press release (Exhibit 99.1). The document does not provide specific financial guidance, management commentary on future earnings, or detailed risk factors within the text of the Form 6-K itself, deferring to the incorporated press release for such disclosures.
Key Facts for Investor Verification
- Verify the full text of the press release (Exhibit 99.1) for the complete "Forward Looking Statements" and detailed study methodology.
- Confirm the specific patient population and tumor types included in the study reporting a 97.7% technical success rate.
- Review the Company's most recent Form 20-F or quarterly reports for actual financial performance, as this filing contains no financial data.
- Monitor regulatory approval status for ProSense® in the specific indications (lung, bone, soft tissues) highlighted in the study.